Skip to content

Clinical trials

Brain Diseases trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Brain Diseases Country / region: Canada Clear all

46 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20102
20111
20124
20134
20143
20151
20165
20174
20183
20192
20204
20213
20221
20233
20241
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Terminated10
Recruiting4
Active, not recruiting3
Withdrawn2
Enrolling by invitation1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of British Columbia4
AbbVie3
AstraZeneca3
TauRx Therapeutics Ltd3
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.3
Centre hospitalier de l'Université de Montréal (CHUM)2
Eli Lilly and Company2
GlaxoSmithKline2
Otsuka Pharmaceutical Development & Commercialization, Inc.2
AbbVie (prior sponsor, Abbott)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Brain Diseases46
Central Nervous System Diseases34
Nervous System Diseases26
Neurodegenerative Diseases17
Alzheimer Disease14
Dementia14
Mental Disorders12
Cerebrovascular Disorders10
Movement Disorders9
Cardiovascular Diseases8

Trials

Showing 76 to 46 of 46. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.